Ruiz-Guzman v. Amvac Chemical Corp.

7 P.3d 795, 141 Wash. 2d 493, 2000 Wash. LEXIS 487

• Court: Washington Supreme Court
• Decided: August 24, 2000
• Docket: No. 68434-1
• Status: Published

Opinions

Bridge, J.

— Pursuant to chapter 2.60 RCW and RAP 16.16, the United States Ninth Circuit Court of Appeals has certified to us two questions involving construction of the Washington product liability act (WPLA), chapter 7.72 RCW. Those questions are:

1. Under the WPLA’s “risk-utility” test, may a plaintiff rely upon an alternative product to show that the challenged product’s risks outweigh the adverse effects of using an “alternative design?”

2. Under Washington law, can a pesticide be an “unavoidably unsafe product” as described in comment k to Restatement (Second) of Torts § 402A?

We accepted certification of the questions, and now answer both in the affirmative.

FACTS

The parties have stipulated to certain facts from the underlying case for purposes of our review. Three of the plaintiffs, Ricardo Ruiz-Guzman, Martin Martinez, and Miguel Farias (hereinafter referred to collectively as “plaintiffs”),¹ worked for apple growers in Mattawa, Washington, in the summer of 1993. Among other things, their duties included mixing, loading, or applying certain pesticides used in their employers’ orchards. Until 1993, Eastern Washington apple growers used a “restricted use” pesticide² called Phosphamidon to control aphid infestations in their orchards. However* Phosphamidon’s manufacturer chose not to renew the pesticide’s federal registration with the Environmental Protection Agency (EPA) for the 1993 growing season. In spring of that year, defendant Amvac Chemical Corporation was told by one of its distributors, defendant Wilbur-Ellis Company, that Washington apple growers wanted to identify a pesticide to replace Phosphamidon as a means of controlling aphids in their orchards. Amvac manufactured Phosdrin, which had been used to control aphid infestations in crops other than apples. Phosdrin was also classified by the EPA as a “restricted use” pesticide, and its label bore a federally approved warning limiting Phosdrin’s permissible uses, among them application in apple orchards, and providing detailed instructions on its use.

Due to Phosdrin’s toxicity, and its anticipated use by Washington apple growers unfamiliar with it, Amvac worked with the Washington State Department of Agriculture (WSDA) to develop additional restrictions on Phosdrin’s sale and use in Washington orchards. WSDA adopted these restrictions, using a fast-track method, known as “Emergency Rules.” The restrictions became effective on June 14, 1993. The rules included restrictions on application techniques and required that training be available for growers using Phosdrin on apples or pears.

On July 13, 1993, Farias reported symptoms after working with Phosdrin, and the next day was diagnosed at Quincy Valley Hospital with a mild toxic reaction to organophosphates. Days later, Martinez and Ruiz-Guzman separately reported symptoms after working with Phosdrin. They were admitted to Sunnyside Hospital and treated for organophosphate exposure.

The relevance and admissibility of the following facts submitted by the Ninth Circuit has not been stipulated to: that on August 30,1993, the WSDA temporarily suspended Phosdrin’s further use on Washington tree fruit orchards pending public hearings; that on June 30, 1994, Amvac requested the cancellation of Phosdrin’s registration, and the EPA cancelled it; and that Phosdrin can no longer be used in the United States.

Plaintiffs originally filed suit against Amvac and Wilbur-Ellis in King County Superior Court in September 1995, and the lawsuit was removed to the United States District Court for the Eastern District of Washington. Following discovery, the district court granted summary judgment, holding, in part, that in the absence of showing an alternative formulation for Phosdrin, plaintiffs had not demonstrated a design defect under Washington law. Alternatively, the court held that Phosdrin was an unavoidably unsafe product under comment k to Restatement (Second) of Torts § 402A. Plaintiffs appealed, and after briefing and oral argument, the Ninth Circuit, as noted above, asked this court to answer two questions. We agreed to do so, and also granted leave to two parties, the Washington Defense Trial Lawyers and the Washington State Trial Lawyers Association Foundation (WSTLA Foundation), to file amicus briefs.

ANALYSIS

I

The threshold question posed by the Ninth Circuit in this case is whether a plaintiff may rely upon an alternative product, under the risk-utility test of the WPLA, to show that a challenged product’s risks outweigh the adverse effects of using an alternative design. Only if this question is answered in the affirmative is the Ninth Circuit’s second question certified to us. Plaintiffs would have us answer the question in the affirmative, while Amvac contends that the answer is more complicated than a simple “yes” or “no.”

Under the WPLA: “Aproduct manufacturer is subject to liability... if the claimant’s harm was proximately caused by the negligence of the manufacturer in that the product was not reasonably safe as designed or not reasonably safe because adequate warnings or instructions were not provided.” RCW 7.72.030(1) (emphasis added). Plaintiffs do not dispute the adequacy of the warnings or instructions provided with the Phosdrin,³ but rather argue that “the product was not reasonably safe as designed. . . .” Id. Addressing this question requires the application of the risk-utility test provided for in the WPLA. Under this balancing test, a product

is not reasonably safe as designed, if, at the time of manufacture, the likelihood that the product would cause the claimant’s harm or similar harms, and the seriousness of those harms, outweighed the burden on the manufacturer to design a product that would have prevented those harms and the adverse effect that an alternative design that was practical and feasible would have on the usefulness of the product.

RCW 7.72.030(l)(a) (emphasis added).

Plaintiffs argue that

[bly using the indefinite article “a” rather than the definite article “the” to describe the product to be compared with the challenged product, the Act, read literally, permits reliance on the existence or feasibility of a product different from the challenged product to establish . . . that the challenged product is “not reasonably safe.”

Opening Br. of Plaintiffs-Appellants at 8.

Amvac does not entirely disagree, stating that reliance upon an alternative product should be permitted “when the alternative product incorporates a design feature that the defendant could have incorporated into the challenged product, at the time it was manufactured, and thereby prevented the plaintiffs harm.” Response Br. of DefendantAppellee at 10-11 (emphasis added). Amvac asserts, however, that an alternative product is not feasible in this instance given that an alternative pointed to by plaintiffs, Phosphamidon, was commercially unavailable. Amvac notes that Phosphamidon’s manufacturer failed to renew its EPA registration, and that even had its registration been renewed, another manufacturer would have held the exclusive rights to Phosphamidon. See Response Br. of Defendant-Appellee at 20.

We have never specifically described the proof necessary to demonstrate the existence of an adequate alternative product under RCW 7.72.030(l)(a). Indeed, both parties cite Lamon v. McDonnell Douglas Corp., 91 Wn.2d 345, 588 P.2d 1346 (1979),⁴ as the only published decision where a plaintiff was allowed to demonstrate a defective design by comparing a challenged product with that of another product from a different manufacturer.

In Lamon, a flight attendant, Lamon, sought damages for injuries she sustained falling through an emergency exit hatch that had been left open, contrary to instructions received during training, by another attendant in an airplane galley. Id. at 346-47. Lamon alleged that the airplane, a DC-10, was defectively designed and manufactured, and that the manufacturer, McDonnell Douglas, had negligently failed to properly warn of a dangerous condition. Id. at 346. A motion for summary judgment was granted to McDonnell Douglas. Id. On appeal, this Court reversed. Id. We referred to an expert’s affidavit that had been introduced before the trial court comparing the escape hatches of a DC-10 and Boeing 747, and wrote that “[t]he comparison of the two hatches in the affidavit raises the inference that a reasonable alternative which poses less risk is feasible.” Id. at 352.

Amvae interprets this to mean that Lamon “simply used the existing 747 design to illustrate the feasibility of a “hinged’ hatch cover that could have been incorporated into the DC-10 and would have prevented her from being harmed.” Response Br. of Defendant-Appellee at 10 (emphasis added). However, this was never stated in the opinion and the plaintiffs disagree with this analysis. In support of their position they refer us to Ayers v. Johnson & Johnson Baby Prods. Co., 117 Wn.2d 747, 818 P.2d 1337 (1991), wherein it was alleged that a baby product was “not reasonably safe” under the WPLA because its packaging contained a warning inadequate to prevent a baby’s harm. Defendants in Ayers had argued that plaintiffs failed to support their claim by establishing the exact wording of an alternate warning, and that “a jury cannot decide that a warning would have prevented an accident without knowing exactly what that warning is.” Id. at 756. We held that no such requirement under the WPLA existed, and that “requiring claimants in failure to warn cases to establish the exact wording of an alternative warning would impose too onerous a burden.” Id.

Importing the logic of Ayers, the plaintiffs here argue that “it would impose ‘too onerous a burden’ on plaintiffs in design defect cases to show not just that other products are adequate substitutes for the defendant’s product, but that the chemical composition in the defendant’s product could be altered to make the product safer and just as effective.” Opening Br. of Plaintiffs-Appellants at 12; see also Soproni v. Polygon Apartment Partners, 137 Wn.2d 319, 330, 971 P.2d 500 (1999) (chiding Court of Appeals for not engaging “in any overt balancing of the risk of Alpine’s product against its utility” by concluding, in essence, “that a product is not unsafe merely because safer designs exist for a given application. . . .”).⁵ Plaintiffs argue in favor of a broad, rather than narrow, interpretation of the term “alternative design” as it is used in the WPLA — one including other products that perform the same function as the challenged product. Reply Br. of Plaintiffs-Appellants at 10. They assert that this would be in keeping with the fact that “a design defect product liability claim is still a strict liability claim” and “the focus is still on the reasonable safety of the product rather than on the reasonableness of the conduct of the manufacturer.” Id. at 10 (quoting Falk v. Keene Corp., 113 Wn.2d 645, 653, 782 P.2d 974 (1989)); see also Soproni, 137 Wn.2d at 330 (embracing this holding in Falk).

In Falk, plaintiffs alleged that companies that had manufactured asbestos were liable for a plaintiffs cancer caused as a result of exposure to that asbestos. There, we held that a trial court had erred in giving jury instructions based on negligence, for we found that strict liability, not ordinary negligence, was the standard adopted by the Legislature in determining manufacturer liability for defectively designed products. Falk further noted that the consumer expectations test in the WPLA should be considered along with its risk-utility test in a product liability case.⁶ Falk, 113 Wn.2d at 651.

In Couch v. Mine Safety Appliances Co., 107 Wn.2d 232, 728 P.2d 585, 78 A.L.R. 4th 139 (1986), we held that “the availability of an alternative, reasonably safe design is not a necessary element of a plaintiffs burden of proof in a product liability action based on defective design.” Id. at 234 (emphasis added). In Couch, a logger was killed as a result of a head injury caused by a tree falling on him, and his wife sued the manufacturer of his safety helmet— alleging that it was not reasonably safe under the WPLA. Presented with a contrary interpretation of the WPLA, we flatly rejected the argument that a “plaintiff bears the burden of proving the existence of a practical and feasible alternative design.” Id. at 239. This was in keeping with an earlier common law holding that “[a] plaintiff may . . . establish that a product is unreasonably dangerous by means of factors other than the existence of alternative design.” Connor v. Skagit Corp., 99 Wn.2d 709, 715, 664 P.2d 1208 (1983) (emphasis added).⁷

We did note in Couch, however, that in cases where a plaintiff seeks to prove liability through the use of only one factor, such as the risk-utility test instead of the consumer expectations test, that factor must be established by a preponderance of the evidence. Couch, 107 Wn.2d at 237 n.4 (citing Connor, 99 Wn.2d at 715-17). In Connor, for example, the plaintiff “chose not to rely on any factors other than the availability of an alternative, safe design in presenting his case to the jury.” Id. Accordingly, the plaintiffs here, by relying upon the risk-utility test and not invoking the consumer expectations test, must prove the existence of an alternative design to Phosdrin. Couch and Connor demonstrate that Washington strict liability analysis is not a one-dimensional, risk-utility test that requires proof of a specific design “defect.” Baughn v. Honda Motor Co., 107 Wn.2d 127, 136, 727 P.2d 655 (1986) (noting that we do not “deem it necessary to apply the type of risk-utility analysis . . . that specifically requires preliminary proof of ‘something wrong’.”) (quoting Perkins v. F.I.E. Corp., 762 F.2d 1250, 1272 (5th Cir. 1985)).

Plaintiffs would like to point to the existence of other aphid-killing pesticides such as Phosphamidon, to show that safer pesticides could serve the same purpose as Phosdrin. Although it is true that a competitor held the patent to Phosphamidon, and allowed its EPA registration to lapse, this could hardly mean that Amvac was free to introduce an alternative means of killing aphids with indifference to its greater risk of harming humans — simply ignoring its statutory burden “to design a product that would have prevented those harms .. . .” RCW 7.72.030(l)(a). For example, if the only means of competing with products that are safer as designed is by introducing an unreasonably unsafe design then it would obviously be far better to yield to the safer products. Most products, after all, do not exist in a vacuum. Lamon, while not directly on point, is helpful here. Lamon did not require that the plaintiff show that it was feasible to incorporate the Boeing 747 hatch design into the DC-10. Nor did the plaintiffs expert’s affidavit quoted in Lamon address this. Lamon, 91 Wn.2d at 348-49. Comparing the two hatches simply raised the inference that a reasonable alternative to the DC-10 hatch which posed less risk was feasible. Id. at 352.

If another product can more safely serve the same purpose as the challenged product at a comparable cost and in a similar manner, a jury should be able to conclude that the risks of the challenged product outweigh its utility. Persuasive authority for this position can be found in the law of products liability as stated in the new Restatement (Third) of Torts § 2 cmt. /., at 24 (1998), which allows a plaintiff to establish an alternative safer design through “other products already available on the market [that] may serve the same or very similar function at lower risk and at comparable cost. Such products may serve as reasonable alternatives to the product in question.” (Emphasis added.) See also, e.g., Restatement (Third) op Torts cmt. d., at 19 (1998) (“How the defendant’s design compares with other, competing designs in actual use is [also] relevant to the issue of whether the defendant’s design is defective.”).

Amvac argues that to allow admission of alternative product design without proving that the design could have been incorporated into the challenged product would be to absolve pesticide applicators for reckless or negligent decisionmaking involving the challenged pesticide. See Response Br. of Defendant-Appellee at 22. However, this is no truer than if Amvac’s own test were met; moreover, it would not logically follow if those applicators were not provided in the first place with pesticides “not reasonably safe as designed .. . .” RCW 7.72.030(1). Indeed, Amvac errs on the side of effectively placing all responsibility for injuries caused by Phosdrin and like products upon their users, which is quite in contrast to the strict product liability regime provided for by the WPLA. There, after all, “the focus is ... on the reasonable safety of the product.” Falk, 113 Wn.2d at 653 (emphasis added). As we have noted, “Once the product is found to be not reasonably safe . . . , the manufacturer is liable for harm proximately caused by the design defect.” Id. at 651 (emphasis added).

Our answer to the first question certified to us is that a plaintiff may satisfy the requirement of showing an adequate alternative design by showing that other products can more safely serve the same function as the challenged product.⁸

II

The second question certified to us, upon an affirmative answer to the first, asks whether, under Washington law, a pesticide can be an “unavoidably unsafe product” as described in comment k to Restatement (Second) of Torts § 402A.

Section 402A establishes strict liability for “ ‘[o]ne who sells any product in a defective condition unreasonably dangerous to the user or consumer or to his property ....’” Ulmer v. Ford Motor Co., 75 Wn.2d 522, 530, 452 P.2d 729 (1969) (quoting approvingly Restatement (Second) of Torts § 402A). However, there is an exception for “unavoidably unsafe products,” which reads as follows:

There are some products which, in the present state of human knowledge, are quite incapable of being made safe for their intended and ordinary use. These are especially common in the field of drugs. An outstanding example is the vaccine for the Pasteur treatment of rabies, which not uncommonly leads to very serious and damaging consequences when it is injected. Since the disease itself invariably leads to a dreadful death, both the marketing and the use of the vaccine are fully justified, notwithstanding the unavoidable high degree of risk which they involve. Such a product, properly prepared, and accompanied by proper directions and warning, is not defective, nor is it unreasonably dangerous. The same is true of many other drugs, vaccines, and the like, many of which for this very reason cannot legally be sold except to physicians, or under the prescription of a physician. It is also true in particular of many new or experimental drugs as to which, because of lack of time and opportunity for sufficient medical experience, there can be no assurance of safety, or perhaps even of purity of ingredients, but such experience as there is justifies the marketing and use of the drug notwithstanding a medically recognizable risk. The seller of such products, again with the qualification that they are properly prepared and marketed, and proper warning is given, where the situation calls for it, is not to be held to strict liability for unfortunate consequences attending their use, merely because he has undertaken to supply the public with an apparently useful and desirable product, attended with a known but apparently reasonable risk.

Restatement (Second) of Torts § 402Acmt. k (1965). There is no debate that this exception has been expressly adopted by this court. Terhune v. A.H. Robins Co., 90 Wn.2d 9, 12, 577 P.2d 975 (1978).

We should note that the comment k exception to strict liability was not expressly provided for by the Legislature in adopting the WPLA, although it is implicit that products that are “unavoidably unsafe” are not products that ever could be “reasonably safe as designed. . . .” RCW 7.72.030(1). Because comment k was not expressly provided for in the WPLA, we must be sparing in its application lest we defeat the letter or policy of the WPLA.

The application of comment k by this court has been confined to a trilogy of cases involving medical products available only through a physician. In the first case, Terhune, we held that the manufacturer of a contraceptive device, the Daikon Shield, would not be liable for injuries caused by its product if adequate warnings and instructions to prescribing physicians were supplied. Terhune, 90 Wn.2d at 13-14. In such a case, “[wjhere a product is available only on prescription or through the services of a physician, the physician acts as a learned intermediary between the manufacturer or seller and the patient.” Id. at 14. The principles of comment k “have their basis in the character of the medical profession and the relationship which exists between the manufacturer, the physician and the patient.” Id. at 16.

The second case in which comment k was applied, Rogers v. Miles Labs., 116 Wn.2d 195, 802 P.2d 1346 (1991), likewise involved a medical product. There, we were confronted with another federal certified question, one asking whether strict liability was applicable to a for-profit pharmaceutical company for injuries that allegedly resulted from the processing and supplying of HIV-contaminated blood products. Id. at 197. We wrote that

[cjomment k justifies an exception from strict liability by focusing on the product and its relative value to society .... Some products are necessary regardless of the risks involved to the user. The alternative would be that a product, essential to sustain the life of some individuals, would not be available— thus resulting in a greater harm to the individual than that risked through use of the product. Blood and blood products fall into this category.

Id. at 204 (emphasis added).

The final case in this trilogy, Young v. Key Pharmaceuticals, Inc., 130 Wn.2d 160, 922 P.2d 59 (1996), was one where a Court of Appeals’ decision, which held that comment k applied to all prescription drugs, was affirmed, in the absence of a constitutional majority, by a 4-4 plurality vote.⁹ The plurality adopted the Court of Appeals’ decision, quoting as follows:

“While there is language in comment k that can be read otherwise, the focus of both Terhune and Rogers is such that we conclude that... a separate determination of whether a product is unavoidably unsafe need not be made on a case-by-case basis if that product is a prescription drug.”

Id. at 170 (footnote omitted) (quoting Young v. Key Pharms., Inc., No. 33070-5-1, slip op. at 2-8 (Wash. Ct. App. June 19, 1995)). The Court of Appeals had also noted that “ ‘it is precisely because they are unavoidably unsafe to some degree that they are prescription drugs.’ ” Id. (citation omitted). The dissent agreed that “[t]he rationale underlying the exception is the recognition that certain products are incapable of being made safe for their intended and ordinary use, but the marketing of such products is justified despite the medically recognizable risk because of the social utility of having the product available.” Id. at 181 (Madsen, J., dissenting) (emphasis added). The issue upon which the dispute between the Young plurality and dissent was centered was on the failure to warn, not on the standard to be applied in defining comment k products.

Both Amvac and the WSTLA Foundation agree that the plurality view in Young “would treat as equal a variety of prescription drugs that have vastly differing social utility,” Amicus Br. of WSTLA Foundation at 17 (emphasis added), and that this is a result arguably incongruent with the social utility reasoning in Terhune and Rogers. Yet, it is not appropriate for us to use this case to accept the WSTLA Foundation’s invitation to “reject the view that all prescription drugs are exempted from strict liability analysis” and exchange it for a product-by-product approach. Id. The determination to be made here is the application of pesticides as a product group to comment k protection. In answering federal certified questions, we do not seek to make broad statements outside of the narrow questions and record before us. Crossler v. Hille, 136 Wn.2d 287, 289, 961 P.2d 327 (1998).

By its own terms, comment k is especially applicable to medical products. The exceptions for medical products recognize the unique protection provided to the consumers of such products by the prescribing physician (and/or pharmacist) intermediary. “[I]t [is] safe to surmise that ordinarily a physician will not prescribe or utilize a product which he does not consider reasonably safe, and that he will take into account the amount of testing, or lack thereof, which has been done with respect to the product.” Terhune, 90 Wn.2d at 16. A physician possesses the medical training to assess adverse health effects of a medical product and to tailor that assessment to a particular patient. As we noted in Terhune, the physician “is concerned with the total health and physical well-being of his patients.... Certainly the insertion of the Daikon Shield requires a physician’s services, his knowledge and his skill. . . . [I]t is he who supplies and inserts the device.” Id. at 15.

In contrast, it may not be safe to surmise that a commercial grower — as the analogous intermediary between manufacturer and ultimate user — will independently evaluate the risks of use of a particular pesticide. While it is true that a pesticide such as Phosdrin is highly regulated, not unlike a prescription drug, analogizing certified pesticide dealers and applicators to medical professionals is probably unwarranted. Moreover, the only two outside authorities that we are referred to in which the application of comment k to pesticides was at issue refused to apply comment k outside the realm of medical products. See Arkansas-Platte & Gulf Partnership v. Dow Chem. Co., 886 F. Supp. 762, 767 (D. Colo. 1995); Kennan v. Dow Chem. Co., 717 F. Supp. 799, 812 (M.D. Fla. 1989).

While pesticides are inherently toxic by definition, including pesticides as a class in comment k would free a pesticide manufacturer from any incentive to make its pesticides safer to humans because they could never be made “safe.” Thus, human safety would be essentially irrelevant in composing the toxicity of a pesticide. Certainly, disregard for human health in the application of comment k would extend that comment’s reach very far from our initial holding that “[t]he principles stated in comment k ... . have their basis in the character of the medical profession and the relationship which exists between manufacturer, the physician and the patient.” Terhune, 90 Wn.2d at 16. However, a determination that pesticides can never be unavoidably unsafe products within the ambit of comment k would seem to defy common sense.¹⁰ Consistent with the social utility reasoning of Rogers, a product-by-product approach to the application of comment k is warranted.

Under this approach, not all products that cannot be made safer would qualify as “unavoidably unsafe” products entitled to comment k’s protection. Instead, the defendant manufacturer of a challenged product would have to demonstrate that an inherently dangerous product is also “necessary regardless of the risks involved to the user.” Rogers, 116 Wn.2d at 204. This would involve, as we held in Rogers, “focusing on the product and its relative value to society . . . .” Id. (emphasis added). Thus, despite the fact that its product cannot be made safer for its intended use, a pesticide manufacturer could demonstrate the product serves an important enough function (e.g., in the realm of food production) so as to justify its unavoidable risks.

Where a claimant under the WPLA could demonstrate the existence of safer alternative pesticides that could serve the same purpose with less risk of harm, the challenged pesticide’s social value could be achieved through the use of another pesticide. Accordingly, the challenged pesticide could not be deemed “necessary regardless of the risks involved to the user.” Rogers, 116 Wn.2d at 204. There need not be a finding of overwhelming social utility. Killing aphids on apple trees might not be of overwhelming social utility, but it might be shown to be substantially important to preserve an apple crop. The test adopted by a federal court, applying Colorado law, is helpful:

For the rule precluding liability for unavoidably unsafe products to apply to a given product, the product’s utility must greatly outweigh the risk created by its use, the risk must be a known one, the product’s benefit must not be achievable in another manner, and the risk must be unavoidable under the state of knowledge existing at the time of manufacture.

Arkansas-Platte & Gulf Partnership, 886 F. Supp. at 767 (citing Camacho v. Honda Motor Co., 741 P.2d 1240, 1244 n.5 (Colo. 1987), cert. dismissed, 485 U.S. 901, 108 S. Ct. 1067, 99 L. Ed. 2d 229 (1988)). This analysis is likewise consistent with our holdings in Terhune and Rogers.

Since we hold that the question of whether a pesticide is governed by comment k is to be determined on a product-by-product basis, as opposed to a blanket exemption like that for medical products, it necessarily follows that the trier of fact should determine a pesticide’s value to society relative to the harm it causes. For example, here the parties debate over whether Phosdrin was primarily used to improve the cosmetic appearance of the apples or to preserve crop yields. This is a question for a jury to resolve.¹¹

Our answer to the second question certified by the Ninth Circuit is “yes,” a pesticide can be an “Unavoidably unsafe product” as described in comment k to Restatement (Second) of Torts § 402A (1965), if its utility greatly outweighs the risks posed by its use.

CONCLUSION

We answer both questions certified by the Ninth Circuit in the affirmative. Under the WPLA’s risk-utility test, a plaintiff may rely upon an alternative product to show that the challenged product’s risks outweigh the adverse effects of using an alternative design. A pesticide can be an “[Unavoidably unsafe product” as described in comment k to Restatement (Second) of Torts § 402A (1965), but only if its utility greatly outweighs the risks posed by its use.

Guy, C.J., and Smith, Johnson, Madsen, Alexander, and Ireland, JJ., concur.

1 The remaining plaintiff, Ignacia Farias, is Miguel’s wife.

2 “Restricted use” pesticides must be registered with both the Environmental Protection Agency (EPA) and. the Washington State Department of Agriculture. Pesticides so classified by the EPA may be distributed only by a licensed pesticide dealer to a certified pesticide applicator or his or her duly authorized representative. See WAC 16-228-164.

3 The parties dispute whether the plaintiffs’ arguments before the district court and before the Ninth Circuit have been consistent, with Amvac contending that the plaintiffs argued inadequacy of warnings or instructions in the district court and then argued unsafe design before the Ninth Circuit. This argument is for the Ninth Circuit to resolve, and is irrelevant to the resolution of the specific questions certified to us. See Kitsap County v. Allstate Ins. Co., 136 Wn.2d 567, 577, 964 P.2d 1173 (1998) (“[W]hen a federal court certifies a question to this court, this court answers only the discrete question that is certified and lacks jurisdiction to go beyond the question presented.”) (citing Louisiana-Pacific Corp. v. Asarco Inc., 131 Wn.2d 587, 604, 934 P.2d 685 (1997)).

4 Although Lamon predates the WPIA’s enactment, it still has “continuing vitality.” Soproni v. Polygon Apartment Partners, 137 Wn.2d 319, 329 n.5, 971 P.2d 500 (1999).

5 Perhaps tellingly, Amvac makes far more of the dissent in Soproni than its majority. Defendant-Appellee Amvac Chemical Corporation’s Resp. to the WSTLA Foundation at 5-6, 7-8.

6 The consumer expectations test is as follows:

In determining whether a product was not reasonably safe under this section, the trier of fact shall consider whether the product was unsafe to an extent beyond that which would be contemplated by the ordinary consumer.

Falk, 113 Wn.2d at 650 (quoting RCW 7.72.030(3)).

7 Connor’s holding “still prevails” under the WPLA. Couch, 107 Wn.2d at 239.

8 The availability and feasibility of such alternatives to Phosdrin, the subject of debate between the parties, is a question for the Ninth Circuit, not this Court, to resolve as part of the underlying case. Kitsap County, 136 Wn.2d at 577. Plaintiffs suggest that the alternative design or product must be “technologically achievable and economically viable.” Plaintiffs-Appellants’ Br. in Answer to Brs. of Amici Curiae. We agree that this standard is in keeping with the statutory requirement that an alternative design be “practical and feasible....” RCW 7.72.030(lXa).

9 Justice Talmadge did not participate.

10 Plaintiffs point out that the weight of comment k commentary addresses its applicability to medical products alone. Plaintiffs-Appellants’ Br. in Answer to Brs. of Amici Curiae at 17-18. However, the comment, by its own terms, applies to all “[u]navoidably unsafe products.” Restatement (Second) of Torts § 402A cmt. k (1965). Thus, its scope is not limited solely to the examples it provides to illustrate that such products “are especially common in the field of drugs.” Id. (emphasis added).

11 In Lewis v. American Cyanamid Co., 155 N.J. 544, 715 A.2d 967 (1998), a case involving a design defect claim involving an insecticide propellant’s flammability, the New Jersey Supreme Court found “disputed issues of material fact regarding the practicality and feasibility” of an alternative propellant. Id. at 979. The defendant manufacturer sought “immunity from liability resulting from its decision to use a more flammable propellant than one that was a suspected teratogen and ozone-depleter.” Id. at 980. The court wrote that “[s]o fact sensitive a determination ... is particularly amenable to risk-utility analysis by a jury.” Id. Accordingly, it held as follows:

[W]e conclude that plaintiff has established a prima facie case that P-22 was a practical and feasible alternative that would have reduced the flammability of the foggers’ propellant.... We take no position, however, on the issue of whether plaintiff has met his burden. This is an issue for the jury to decide at retrial.

Id.